Maria Craig
Overview
Explore the profile of Maria Craig including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
202
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Royle M, Callen J, Craig M
Health Inf Manag
. 2009 May;
32(1):5-12.
PMID: 19468147
The aim of this study was to analyse the inpatient statistics collection relating to stroke patients admitted to a major teaching hospital, with particular reference to length of stay, and...
12.
Strippoli G, Craig M, Schena F, Craig J
J Am Soc Nephrol
. 2005 Sep;
16(10):3081-91.
PMID: 16135776
The objective of this study was to evaluate the comparative effects of antihypertensive agents in patients with diabetes and normoalbuminuria. Randomized, controlled trials that compared any antihypertensive agent with placebo...
13.
Laron Z, Lewy H, Wilderman I, Casu A, Willis J, Redondo M, et al.
Isr Med Assoc J
. 2005 Jun;
7(6):381-4.
PMID: 15984382
Background: Type 1 childhood-onset diabetes mellitus has a multifactorial origin involving an interplay between genetic and environmental factors. We have previously shown that many children who subsequently develop T1DM have...
14.
Maguire A, Chan A, Cusumano J, Hing S, Craig M, Silink M, et al.
Diabetes Care
. 2005 Mar;
28(3):509-13.
PMID: 15735179
Objective: Current guidelines recommend annual retinopathy screening 2 years after onset (for pubertal-onset type 1 diabetes) and after 5 years (or age 11, whichever is earlier) for prepubertal onset. Our...
15.
Strippoli G, Craig M, Deeks J, Schena F, Craig J
BMJ
. 2004 Oct;
329(7470):828.
PMID: 15459003
Objective: To evaluate the effects of angiotensin converting enzyme (ACE) inhibitors and angiotensin II receptor antagonists (AIIRAs) on renal outcomes and all cause mortality in patients with diabetic nephropathy. Data...